Comparison of Neural Correlates of Reactive Inhibition in Cocaine, Heroin, and Polydrug Users through a Contextual Go/No-Go Task Using Event-Related Potentials.

cocaine error-processing event-related potentials heroin inhibition polydrug substance use disorder (SUD)

Journal

Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988

Informations de publication

Date de publication:
08 Jul 2022
Historique:
received: 05 05 2022
revised: 29 06 2022
accepted: 05 07 2022
entrez: 14 9 2022
pubmed: 15 9 2022
medline: 15 9 2022
Statut: epublish

Résumé

Recent global data indicates a worldwide increase in polydrug use associated with a shift from recreational to productive habits of consumption. Such non-responsible abuse of substances (alcohol, cocaine, heroin, etc.) is likely to lead to addictive disorders that are characterized by various neuropsychopharmacological effects. A main cognitive function involved in the onset and long-term maintenance of addiction is reactive inhibition, i.e., the ability to withhold a prepotent motor dominant response. In the present study, 63 (poly)drug user patients who were undergoing a detoxification program, in addition to 19 healthy controls matched for gender, age, and education, were subjected to a "contextual Go/No-Go task" with concomitant electroencephalography. Stimuli were superimposed on three contextual backgrounds: control (black screen), drug-unrelated (neutral pictures), or drug-related (pictures related to drug consumption). Of these patients, 23 were cocaine users (CU), 21 were heroin users (HU), and 19 were polydrug users (PDU). The main results showed that (1) at the behavioral level, more commission errors occurred with the PDU patients compared to the healthy controls; (2) at the neurophysiological level, specific alterations were found on classical event-related potentials that index reactive inhibition. Indeed, the higher rate of errors in the PDU group was subtended by both reduced amplitude and latency on the ∆N2 component and increased ∆P3 latency compared to controls. These data clearly suggest a more deleterious impact of polydrug use on inhibitory functions. In addition, our results provide evidence of reduced ERN amplitude in cocaine users, suggesting that impaired performance monitoring and error-processing may support impaired awareness, thereby preventing these patients from changing their behaviors.

Identifiants

pubmed: 36101410
pii: biology11071029
doi: 10.3390/biology11071029
pmc: PMC9312501
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Physiol Behav. 2019 Apr 1;202:62-68
pubmed: 30711532
J Stud Alcohol. 1996 Nov;57(6):585-90
pubmed: 8913988
Front Psychiatry. 2013 Dec 27;4:179
pubmed: 24409155
Drug Alcohol Depend. 2014 Dec 1;145:1-33
pubmed: 25195081
J Neurosci. 2007 Nov 14;27(46):12700-6
pubmed: 18003850
Prog Brain Res. 2016;224:85-103
pubmed: 26822355
Nat Rev Neurosci. 2011 Oct 20;12(11):652-69
pubmed: 22011681
Am Psychol. 2016 Nov;71(8):670-679
pubmed: 27977239
Biol Psychol. 2007 Apr;75(1):45-51
pubmed: 17196732
Lancet Psychiatry. 2016 Aug;3(8):760-773
pubmed: 27475769
Neuropsychopharmacology. 2022 Jan;47(1):276-291
pubmed: 34408275
Psychol Med. 1999 Jan;29(1):199-212
pubmed: 10077308
J Neurosci. 2003 Aug 27;23(21):7839-43
pubmed: 12944513
Prog Brain Res. 2016;224:285-304
pubmed: 26822363
PLoS One. 2012;7(5):e37466
pubmed: 22616012
Psychopharmacology (Berl). 2017 Nov;234(21):3195-3205
pubmed: 28779309
Neurosci Biobehav Rev. 2020 Mar;110:3-27
pubmed: 30179633
Sci China C Life Sci. 2009 Aug;52(8):780-8
pubmed: 19727597
Front Psychiatry. 2019 Dec 23;10:877
pubmed: 31920740
Psychopharmacology (Berl). 2020 Apr;237(4):1055-1062
pubmed: 31915860
JAMA Netw Open. 2020 Jan 3;3(1):e1918514
pubmed: 31899527
Eur J Pharmacol. 2010 Jan 10;626(1):104-12
pubmed: 19836375
Addict Behav. 2007 May;32(5):950-66
pubmed: 16876962
J Psychiatry Neurosci. 2014 May;39(3):149-69
pubmed: 24359877
Neuropharmacology. 2014 Jul;82:151-60
pubmed: 23507565
CNS Spectr. 2014 Jun;19(3):231-8
pubmed: 23919984
Addict Biol. 2021 Mar;26(2):e12902
pubmed: 32267062
PLoS One. 2012;7(6):e39830
pubmed: 22768136
Drug Alcohol Depend. 2017 Mar 01;172:21-33
pubmed: 28107679
Pharmacol Biochem Behav. 2007 Feb;86(2):263-83
pubmed: 17116324
J Psychiatry Neurosci. 2021 Nov 9;46(6):E615-E627
pubmed: 34753790
Dialogues Clin Neurosci. 2019 Sep;21(3):281-290
pubmed: 31749652
Neurology. 2014 Jun 10;82(23):2127-38
pubmed: 24814849
Biol Psychiatry. 2002 Jan 15;51(2):134-42
pubmed: 11822992
Neuron. 2018 Jun 6;98(5):886-903
pubmed: 29879391
Psychol Addict Behav. 2010 Mar;24(1):137-44
pubmed: 20307121
Brain Cogn. 2004 Nov;56(2):165-76
pubmed: 15518933
J Abnorm Psychol. 2020 Jan;129(1):29-37
pubmed: 31868385
Hist Educ. 2015;44(1):25-43
pubmed: 27499559
Trends Cogn Sci. 2005 Apr;9(4):195-201
pubmed: 15808502
Front Psychiatry. 2014 Jan 10;4:185
pubmed: 24454294
Eur Psychiatry. 1998;13(1):26-34
pubmed: 19698595
Am J Psychiatry. 2002 Oct;159(10):1642-52
pubmed: 12359667
Psychol Sci Public Interest. 2019 Oct;20(2):96-127
pubmed: 31591935
Psychol Rev. 2002 Oct;109(4):679-709
pubmed: 12374324
Trends Cogn Sci. 2009 Sep;13(9):372-80
pubmed: 19716751
Clin EEG Neurosci. 2014 Apr;45(2):67-76
pubmed: 24104954
Neuropharmacology. 2004;47 Suppl 1:3-13
pubmed: 15464121
J Psychopharmacol. 1999 Dec;13(4):337-45
pubmed: 10667609
Acta Psychol (Amst). 1999 Apr;101(2-3):267-91
pubmed: 10344188
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
pubmed: 8401595
Psychiatry Res. 2004 Jul 30;131(2):135-45
pubmed: 15313520
Neuropsychiatr Dis Treat. 2013;9:1835-45
pubmed: 24348040
Exp Clin Psychopharmacol. 2003 Aug;11(3):210-7
pubmed: 12940500
Biol Psychiatry. 2004 Mar 1;55(5):531-7
pubmed: 15023582

Auteurs

Clémence Dousset (C)

Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (ULB), 4 Place Vangehuchten, 1020 Brussels, Belgium.

Christie Chenut (C)

Substance Abuse Unit 73, CHU Brugmann, 4 Place Vangehuchten, 1020 Brussels, Belgium.

Hendrik Kajosch (H)

Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (ULB), 4 Place Vangehuchten, 1020 Brussels, Belgium.

Charles Kornreich (C)

Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (ULB), 4 Place Vangehuchten, 1020 Brussels, Belgium.

Salvatore Campanella (S)

Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (ULB), 4 Place Vangehuchten, 1020 Brussels, Belgium.

Classifications MeSH